A Phase 1 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies
The goal of this clinical research study is to find the highest tolerable dose of the study drug AMG 397 that can be given to patients with multiple myeloma (MM), non-Hodgkin’s lymphoma (NHL), or acute myeloid leukemia (AML) that is relapsed (has come back) or refractory (has not responded to treatment). The safety and effects of this drug will also be studied. MD Anderson will only enroll participants with AML. This is the first study using AMG 397 in humans.
Disease Group: Malignant neoplasms stated as primary lymphoid haematopoietic
Treatment Agent: AMG 397
Treatment Location: Both at MD Anderson & Other Sites
Sponsor: Amgen Inc.
IRB Review and Approval Date: 11/08/2018
Recruitment Status: Open
Projected Accrual: 90
Information and next steps
Malignant neoplasms stated as primary lymphoid haematopoietic
For general questions about clinical trials: